Biomedicine & Pharmacotherapy (Dec 2019)

Xiaoerfupi alleviates the symptoms of functional dyspepsia by regulating the HTR3A and c-FOS

  • Enhui Ji,
  • Tingting Wang,
  • Feifei Guo,
  • Yi Zhang,
  • Chunyu Tang,
  • Daifeng Tang,
  • Junying Wei,
  • Hongjun Yang,
  • Minghua Xian

Journal volume & issue
Vol. 120

Abstract

Read online

Aim: To evaluate whether Xiaoerfupi (XEFP), a traditional Chinese medicine formula, can ameliorate functional dyspepsia (FD) through regulation of the HTR3A and c-FOS. Method: The FD rat model was established through administration of iodoacetamide (IA) and interval fasting. XEFP group rats received XEFP for 3 weeks. Detection of gastric emptying and gastrin were performed to assess the interventional effect of XEFP. The constituents of XEFP were submitted to BATMAN-TCM, an online bioinformatics analysis tool, to predict the targets related to dyspepsia. Furthermore, the prediction was validated via Western blot assay. Results: XEFP enhanced gastric emptying of rats (XEFP middle dose vs. FD model: 71.87 ± 15.21% vs. 30.07 ± 12.76%, P < 0.01) and simultaneously increased gastrin in FD rats (XEFP middle dose vs. FD model: 63.61 ± 17.90 vs. 26.14 ± 7.78 pg/ml, P < 0.01). KEGG enrichment analysis revealed that the neuroactive ligand-receptor interaction was successfully enriched (P-value = 2.2E-13, Benjamini = 2.0E-11). Combining different Bioinformatics analysis implied that XEFP regulates HTR3A and c-FOS. Subsequently molecular biological studies confirmed that the expression of HTR3A and c-FOS in the model group was upregulated in rats in comparison with the control group. Furthermore, the expression of HTR3A and c-FOS in the XEFP group (middle dose) compared with the model group was significantly reduced (P < 0.01). Conclusion: XEFP may ameliorate FD through regulation of the HTR3A and c-FOS.

Keywords